RESUMO
Despite the spread of chloroquine-resistant Plasmodium falciparum throughout sub-Saharan Africa, chloroquine (CQ) remains the first-line treatment for uncomplicated infection in most countries. To assess the efficacy of CQ and sulphadoxine-pyrimethamine (SP) in Zambia, studies using a standardized 14-day in vivo test were conducted at 6 geographically representative sites. Febrile children < or = 5 years of age were treated with standard doses of CQ or SP and monitored for parasitological failure (using modified WHO criteria) and clinical failure (fever with parasitaemia after completion of therapy). RII/RIII (high to moderate level) parasitological failures were identified in 34% to 70% of CQ-treated children (total N = 300) at the 6 sites and clinical failures in 31% to 48%. SP testing at 2 sites identified RII/RIII failures in 3% and 17% of children and only 1 clinical failure at each site. Because of the high levels of CQ resistance identified in these trials, the Ministry of Health of Zambia convened a national consensus meeting which recommended that Zambia's national malaria treatment policy be modified to make SP available at all health facilities for use in persons who fail initial therapy with CQ. In addition, selected sites, staff, and the methodology from these studies were used to implement a sentinel surveillance system for antimalarial drug efficacy. This systematic approach to antimalarial drug efficacy testing could be easily replicated in other countries seeking to reassess their malaria treatment policies.
Assuntos
Política de Saúde , Malária Falciparum/tratamento farmacológico , Formulação de Políticas , Antimaláricos/antagonistas & inibidores , Antimaláricos/uso terapêutico , Criança , Pré-Escolar , Cloroquina/antagonistas & inibidores , Cloroquina/uso terapêutico , Combinação de Medicamentos , Avaliação de Medicamentos , Resistência a Medicamentos , Feminino , Humanos , Lactente , Malária Falciparum/parasitologia , Masculino , Parasitemia/tratamento farmacológico , Parasitemia/parasitologia , Pirimetamina/antagonistas & inibidores , Pirimetamina/uso terapêutico , Estatística como Assunto , Sulfadoxina/antagonistas & inibidores , Sulfadoxina/uso terapêutico , Fatores de Tempo , ZâmbiaRESUMO
Chloroquine-resistant malaria is a major public health threat in sub-Saharan Africa. While a few countries have already replaced chloroquine as the first-line therapy for uncomplicated malaria or are in the process of doing so, other countries are faced with the complicated task of assessing the current status of drug resistance, making national policy-level decisions about whether to replace chloroquine or not, and initiating a monitoring system to track changes in the efficacy of malaria therapy. There is currently no standardized approach for collecting and interpreting data on therapy efficacy. There is also no agreement as to how much chloroquine resistance or treatment failure is acceptable and how much warrants a change in treatment policy. Using data collected in 10 sites in eastern and southern Africa between 1990 and 1996, we have assessed the therapeutic response to chloroquine and investigated predictors of clinical success or failure. Based on these experiences and analyses, a standardized protocol for in vivo studies of the efficacy of malaria therapy and for approaches to designing monitoring systems are proposed. The process of making policy-level decisions based on data collected by these systems is also discussed.